{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:14:50Z","timestamp":1783401290973,"version":"3.54.6"},"reference-count":81,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>KRAS is one of the most frequently mutated oncogenes in human cancer and has long been considered an \u201cundruggable\u201d therapeutic target because of its high affinity for guanine nucleotides and limited druggable binding pockets. Recent advances in structural biology and molecular pharmacology have transformed this paradigm, leading to the successful development of KRAS G12C inhibitors such as sotorasib and adagrasib. These agents established proof-of-concept for direct KRAS inhibition and marked an important advance in precision oncology. However, intrinsic and acquired resistance mechanisms, adaptive signaling reactivation, and tumor heterogeneity continue to limit the durability of clinical responses. Therapeutic development has rapidly expanded beyond KRAS G12C toward broader strategies including KRAS G12D inhibitors, pan-RAS and RAS(ON) inhibitors, degraders, and biomarker-guided combination approaches. In parallel, circulating tumor DNA (ctDNA) and other biomarker-driven strategies are increasingly enabling dynamic monitoring of treatment response, minimal residual disease, and resistance evolution. In this review, we summarize the molecular biology and conformational regulation of KRAS signaling, recent advances in allele-specific and pan-RAS therapeutic strategies, mechanisms of resistance, and emerging precision oncology frameworks for KRAS-mutant cancers.<\/jats:p>","DOI":"10.3390\/ijms27135796","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:55:11Z","timestamp":1782780911000},"page":"5796","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7511-7009","authenticated-orcid":false,"given":"Yoshihito","family":"Kano","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-Ku, Tokyo 113-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The Frequency of Ras Mutations in Cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: Mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.semcdb.2016.06.006","article-title":"New structural and functional insight into the regulation of Ras","volume":"58","author":"Kano","year":"2016","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS Proteins and Their Regulators in Human Disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-15-1105","article-title":"Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State","volume":"6","author":"Patricelli","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","article-title":"Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor","volume":"172","author":"Janes","year":"2018","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41467-018-08115-8","article-title":"Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation","volume":"10","author":"Kano","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"8859","DOI":"10.1038\/ncomms9859","article-title":"Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis","volume":"6","author":"Bunda","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: Is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","article-title":"The current state of the art and future trends in RAS-targeted cancer therapies","volume":"19","author":"Punekar","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/2159-8290.CD-21-1331","article-title":"Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants","volume":"12","author":"Hofmann","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.1038\/s41467-021-26526-y","article-title":"The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors","volume":"12","author":"Gebregiworgis","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41556-018-0169-1","article-title":"RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers","volume":"20","author":"Nichols","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"14093","DOI":"10.1074\/jbc.272.22.14093","article-title":"Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo","volume":"272","author":"Rowell","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"14459","DOI":"10.1074\/jbc.272.22.14459","article-title":"K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors","volume":"272","author":"Whyte","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s10555-020-09902-w","article-title":"K-Ras prenylation as a potential anticancer target","volume":"39","author":"Baranyi","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","article-title":"Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors","volume":"63","author":"Lanman","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1200\/JCO.22.02524","article-title":"Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100","volume":"41","author":"Dy","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: A randomised, open-label, phase 3 trial","volume":"401","author":"Johnson","year":"2023","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","article-title":"Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition","volume":"26","author":"Ryan","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation","volume":"387","author":"Riely","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.23.00046","article-title":"Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases","volume":"41","author":"Negrao","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e2300447","DOI":"10.1200\/PO.23.00447","article-title":"Safety and Intracranial Activity of Adagrasib in Patients With KRASG12C-Mutated Non-Small-Cell Lung Cancer and Untreated CNS Metastases in the KRYSTAL-1 Trial: A Case Series","volume":"8","author":"Bernstein","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","article-title":"Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer","volume":"14","author":"Yaeger","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1200\/JCO-24-02026","article-title":"Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator\u2019s Choice in Chemorefractory KRAS G12C Colorectal Cancer","volume":"43","author":"Pietrantonio","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired Resistance to KRASG12C Inhibition in Cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","article-title":"Diverse alterations associated with resistance to KRAS(G12C) inhibition","volume":"599","author":"Zhao","year":"2021","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41591-023-02696-8","article-title":"Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: A phase 1b trial","volume":"30","author":"Desai","year":"2024","journal-title":"Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2303810","article-title":"Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation","volume":"389","author":"Sacher","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/s41591-024-03401-z","article-title":"Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: A phase 2b trial","volume":"31","author":"Shi","year":"2025","journal-title":"Nat. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S2468-1253(25)00267-5","article-title":"Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): Two open-label, non-randomised phase 1\/2 trials","volume":"11","author":"Li","year":"2026","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Peng, S., Zhang, Y., Lin, X., Si, C., Van Horn, R.D., Dempsey, J.A., Goetz, E., Evans, R.J., Farber, A., and Vandekopple, M.J. (2026). Characterization of KRASG12C inhibitor olomorasib single-agent and combination with activity in KRASG12C-mutant models. Nat. Commun.","DOI":"10.1038\/s41467-026-72650-y"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1038\/s41467-026-69943-7","article-title":"Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: A first-in-human study","volume":"17","author":"Hollebecque","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41392-025-02274-z","article-title":"Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation","volume":"10","author":"Ruan","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41416-025-03286-w","article-title":"Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer","volume":"134","author":"Yamamoto","year":"2026","journal-title":"Br. J. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"16173","DOI":"10.1021\/acs.jmedchem.2c01438","article-title":"JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors","volume":"65","author":"Lorthiois","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/j.ijrobp.2023.10.073","article-title":"KontRASt-02: A Phase III Trial Investigating the Efficacy and Safety of the KRASG12C Inhibitor JDQ443 vs. Docetaxel in Patients with Previously Treated, Locally Advanced or Metastatic, KRAS G12C-Mutated NSCLC","volume":"118","author":"Cappuzzo","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jtho.2024.04.007","article-title":"Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib","volume":"19","author":"Ernst","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e000060","DOI":"10.1136\/esmoopen-2016-000060","article-title":"Mechanisms of resistance to EGFR-targeted drugs: Lung cancer","volume":"1","author":"Morgillo","year":"2016","journal-title":"ESMO Open"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","article-title":"Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer","volume":"8","author":"Yoda","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-19-3822","article-title":"NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma","volume":"80","author":"Ladumor","year":"2020","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","article-title":"Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer","volume":"13","author":"Kemp","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1158\/1078-0432.CCR-19-2803","article-title":"A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer","volume":"26","author":"Romero","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"17796","DOI":"10.1038\/s41598-022-22668-1","article-title":"Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy","volume":"12","author":"Issahaku","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_54","unstructured":"ClinicalTrials.gov (2026, May 25). Study of MRTX1133 in Patients with Advanced Solid Tumors Harboring a KRAS G12D Mutation, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05737706."},{"key":"ref_55","unstructured":"ClinicalTrials.gov (2026, May 25). Study of RMC-9805 in Participants with KRAS G12D-Mutant Solid Tumors 2024, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06040541."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ccell.2017.12.004","article-title":"Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer","volume":"33","author":"Yaeger","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","article-title":"Pan-KRAS inhibitor disables oncogenic signalling and tumour growth","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa2505783","article-title":"Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer","volume":"394","author":"Wolpin","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"O\u2019Reilly, E.M., Wainberg, Z.A., Hendifar, A.E., Borad, M.J., Pietrantonio, F., Pant, S., Hammel, P., Cremolini, C., Manji, G.A., and Oberstein, P.E. (2026). Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2605555"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/2159-8290.CD-20-0142","article-title":"BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition","volume":"11","author":"Hofmann","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","article-title":"Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs","volume":"6","author":"Bond","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1126\/science.adm8684","article-title":"Targeting cancer with small-molecule pan-KRAS degraders","volume":"385","author":"Popow","year":"2024","journal-title":"Science"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1021\/acs.jmedchem.3c01622","article-title":"Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRASG12D","volume":"67","author":"Zhou","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41392-025-02172-4","article-title":"Breaking down KRAS: Small-molecule degraders for cancer therapy","volume":"10","author":"Kos","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e2113180119","DOI":"10.1073\/pnas.2113180119","article-title":"Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides","volume":"119","author":"Wang","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"8696","DOI":"10.1038\/s41467-025-63718-2","article-title":"Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: A phase I study with immunological correlates","volume":"16","author":"Kalluri","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","article-title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: The phase 1 AMPLIFY-201 trial","volume":"30","author":"Pant","year":"2024","journal-title":"Nat. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1158\/1078-0432.CCR-23-1212","article-title":"Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations","volume":"30","author":"Linette","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1172\/JCI134915","article-title":"mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer","volume":"130","author":"Cafri","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1038\/s41467-023-42010-1","article-title":"KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors","volume":"14","author":"Lu","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1038\/s41467-019-10419-2","article-title":"KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe","volume":"10","author":"Bery","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1021\/acscentsci.0c00514","article-title":"GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf","volume":"6","author":"Zhang","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5831","DOI":"10.1038\/s41598-017-05889-7","article-title":"An engineered protein antagonist of K-Ras\/B-Raf interaction","volume":"7","author":"Kauke","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Ran\u0111elovi\u0107, I., Ny\u00edri, K., Kopp\u00e1ny, G., Baranyi, M., T\u00f3v\u00e1ri, J., Kigy\u00f3s, A., T\u00edm\u00e1r, J., V\u00e9rtessy, B.G., and Grolmusz, V. (2024). Gluing GAP to RAS Mutants: A New Approach to an Old Problem in Cancer Drug Development. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052572"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/1078-0432.CCR-17-1841","article-title":"Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer","volume":"24","author":"Arbour","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","article-title":"Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer","volume":"29","author":"Kotani","year":"2023","journal-title":"Nat. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41591-019-0561-9","article-title":"Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers","volume":"25","author":"Parikh","year":"2019","journal-title":"Nat. Med."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Noji, R., Tohyama, K., Nakamura, S., Naito, T., Oikawa, Y., Kuroshima, T., Tomioka, H., Michi, Y., Ikeda, S., and Asakage, T. (2024). Dynamic Changes in Circulating Tumor DNA During Immunotherapy for Head and Neck Cancer: SHIZUKU-HN Study. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26010235"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: Towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat. Rev. Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/13\/5796\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:23:20Z","timestamp":1783398200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/13\/5796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":81,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ijms27135796"],"URL":"https:\/\/doi.org\/10.3390\/ijms27135796","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]}}}